On May 19, 2018, the “Seminar for the Treatment of GBM II/III Clinical Trial of Chlorogenic Acid Injection”organized by our company (sponsor) was successfully completed.
Twenty-two experts from 9 clinical research centers such as Beijing TiantanHospital, Peking Union Medical College Hospital and etc,and the experts fromthe Chinese Academy of Medical Sciences Institute of Materia Medica, put forward their own opinions based on the data of various aspects of chlorogenic acid injection. All the participating experts reached consensus on the trial protocol.
Chlorogenic acid injection is a type 1.2 innovative drug that Sichuan Jiuzhang Company has completely independent intellectual property rights for the treatment of gliomas. In 2013, it was approved by the CFDA clinical trial and completed the Phase I clinical trial on September 15, 2017.